Roche, PTC will now get an FDA decision on their SMA drug in 6 months — facing off with Biogen, Novartis

A major competitor to Biogen’s Spinraza franchise could arrive as early as this coming May, as Roche and its biotech partner obtained a priority review for risdiplam.